ABVC BioPharma, Inc.
ABVC Healthcare Biotechnology
ABVC BioPharma, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $509,600.00, up 234.4% from fiscal 2023. In the quarter to June 2026, revenue grew 66,233.3%, EPS grew 76.9% and free cash flow grew 72.7%, each against the same quarter a year earlier.
Follow ABVC
ABVC BioPharma, Inc. (ABVC) EV/Sales
As of 16 October 2026, ABVC BioPharma, Inc. (ABVC) trades at a EV/Sales of 19.6×. Over the past ten years it has ranged from 0.0× (June 2018) to 66,486× (January 2019); the current reading is higher than 38% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2024 | 15.1× | (70.43%) |
| FY2023 | 51.1× | 133.35% |
| FY2022 | 21.9× | (90.33%) |
| FY2021 | 226× | 8.43% |
| FY2020 | 209× | 90.24% |
| FY2019 | 110× | (99.83%) |
| FY2018 | 63,320× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2025 | 54.8× | 263.14% |
| Dec 2024 | 15.1× | (29.86%) |
| Sep 2024 | 21.5× | (75.21%) |
| Jun 2024 | 86.8× | (86.20%) |
| 24 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ATOS Atossa Therapeutics, Inc. compare | −7.0× |
| PLRZ Polyrizon Ltd. compare | n/m |
| IMMP Prima BioMed Ltd compare | n/m |
| EVAX Evaxion A/S - Sponsored ADR compare | 1.3× |
| BYSI BeyondSpring Inc. compare | 13.8× |
| ABVC ABVC BioPharma, Inc. | 19.6× |
| IGC IGC Pharma, Inc. compare | 23.4× |
| MCRB Seres Therapeutics, Inc. compare | 58.8× |
| CYAD Celyad SA compare | — |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)